These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34107794)

  • 1. Continuation and Discontinuation Rates of Biologics in Dermatology Patients During COVID-19 Pandemic.
    Cohen SR; Kahn JS; Gao DX; Fiumara K; Lam A; Dumont N; Rosmarin D
    J Cutan Med Surg; 2021; 25(6):646-647. PubMed ID: 34107794
    [No Abstract]   [Full Text] [Related]  

  • 2. Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto.
    Georgakopoulos JR; Yeung J
    J Cutan Med Surg; 2020; 24(4):424-425. PubMed ID: 32475151
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy.
    Holcomb ZE; Santillan MR; Morss-Walton PC; Salian P; Her MJ; Giannotti NM; Kimball AB; Porter ML
    J Am Acad Dermatol; 2020 Oct; 83(4):1215-1218. PubMed ID: 32622141
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration.
    Bragazzi NL; Riccò M; Pacifico A; Malagoli P; Kridin K; Pigatto P; Damiani G
    Dermatol Ther; 2020 Jul; 33(4):e13508. PubMed ID: 32415727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?
    Megna M; Fabbrocini G; Marasca C
    Int J Dermatol; 2020 Sep; 59(9):1144-1145. PubMed ID: 32710548
    [No Abstract]   [Full Text] [Related]  

  • 6. Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations.
    Waldman RA; Grant-Kels JM
    J Am Acad Dermatol; 2021 Nov; 85(5):1113-1116. PubMed ID: 34437985
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence following guidelines: Another COVID-19 paradox.
    Heymann WR
    J Am Acad Dermatol; 2021 Jan; 84(1):37-38. PubMed ID: 33130184
    [No Abstract]   [Full Text] [Related]  

  • 8. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.
    Ghazawi FM; Lim M; Dutz JP; Kirchhof MG
    Int J Dermatol; 2020 Sep; 59(9):1043-1056. PubMed ID: 32621284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.
    Galimberti F; McBride J; Cronin M; Li Y; Fox J; Abrouk M; Herbst A; Kirsner RS
    Clin Dermatol; 2020; 38(6):775-780. PubMed ID: 32419721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea.
    Cho SI; Kim YE; Jo SJ
    Br J Dermatol; 2021 Feb; 184(2):296-303. PubMed ID: 32875557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatology Teleteaching during the COVID-19 Pandemic.
    Plachouri KM; Mulita F; Georgiou S
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):185-186. PubMed ID: 33291205
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic.
    Sanchez DP; Kirsner RS; Lev-Tov H
    J Am Acad Dermatol; 2020 Jul; 83(1):288-292. PubMed ID: 32380214
    [No Abstract]   [Full Text] [Related]  

  • 13. Disparities in SARS-CoV-2 Testing in Massachusetts During the COVID-19 Pandemic.
    Dryden-Peterson S; Velásquez GE; Stopka TJ; Davey S; Lockman S; Ojikutu BO
    JAMA Netw Open; 2021 Feb; 4(2):e2037067. PubMed ID: 33560423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the COVID-19 pandemic on inpatient dermatology: a multicentre study from Hubei, China.
    Zhang Y; Wen J; Alamgir M; Xie J; Jing H; Fang M; Wang J; Zhang M; Meng Z; Yang L; Tao J
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):e179-e181. PubMed ID: 33220091
    [No Abstract]   [Full Text] [Related]  

  • 15. The new pandemic COVID-19: I.
    Vassileva S; Drenovska K; Lambert WC; Schwartz RA
    Clin Dermatol; 2021; 39(1):1-4. PubMed ID: 33972035
    [No Abstract]   [Full Text] [Related]  

  • 16. Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.
    Nassim D; Jfri A; Litvinov IV; Netchiporouk E
    J Cutan Med Surg; 2020; 24(4):420-421. PubMed ID: 32449619
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of COVID-19 pandemic on psoriatic patients dermatology admissions and biologic treatment adherences: A single-center retrospective study.
    Özdemir AK; Hayran Y; Şen O; Aktaş A
    J Cosmet Dermatol; 2021 Nov; 20(11):3362-3363. PubMed ID: 34633748
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.
    Karadag AS; Aslan Kayıran M; Lotti T; Wollina U
    Dermatol Ther; 2020 Sep; 33(5):e13686. PubMed ID: 32458530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?
    Shanshal M
    J Drugs Dermatol; 2020 Apr; 19(4):436. PubMed ID: 32401460
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China.
    Zhao L; Du H; Alamgir M; Yang J; Miao X; Jiang B; Xia Y; Lou Y; Wang Y; Shen C; Zhu J; Chung WH; Li Y; Tao J
    Eur J Dermatol; 2020 Dec; 30(6):738-740. PubMed ID: 33459264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.